Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 28, 2017 08:30 ET | Source: CardioDx

American Heart Association's New Scientific Statement Deems the Corus CAD Test Valid and Useful for Clinicians Evaluating Obstructive CAD

REDWOOD CITY, CA--(Marketwired - Sep 28, 2017) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today that in a Scientific Statement by the...
August 08, 2017 13:19 ET | Source: CDx Diagnostics

UPDATE - WATS3D Shown to be over 4X More Effective in Detecting High-Grade Dysplasia and Esophageal Adenocarcinoma

SUFFERN, NY--(Marketwired - Aug 8, 2017) - CDx Diagnostics, developer of the WATS3D biopsy, or Wide Area Transepithelial Sampling with 3D Tissue Analysis for the detection and surveillance of...
August 08, 2017 07:00 ET | Source: CDx Diagnostics

WATS3D Shown to be over 4X More Effective in Detecting High-Grade Dysplasia and Esophageal Adenocarcinoma

SUFFERN, NY--(Marketwired - Aug 8, 2017) - CDx Diagnostics, developer of the WATS3D biopsy, or Wide Area Transepithelial Sampling with 3D Tissue Analysis for the detection and surveillance of...
July 05, 2017 16:15 ET | Source: VIVUS Inc.

VIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation

CAMPBELL, CA--(Marketwired - Jul 5, 2017) - VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Actavis Laboratories FL (Actavis) resolving patent...
April 12, 2017 08:00 ET | Source: CardioDx

New Study Published in The American Journal of Medicine Expands the Clinical Evidence Underscoring the Value of the Corus(R) CAD Blood Test to Help Safely Direct Cardiovascular Care

REDWOOD CITY, CA--(Marketwired - Apr 12, 2017) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today the publication of results from the...
February 06, 2017 08:00 ET | Source: CardioDx

PROMISE Substudy Results, Published in the American Heart Journal, Provide Independent Validation of the Clinical Value of the Corus(R) CAD Blood Test to Accurately Identify Patients with Obstructive CAD

REDWOOD CITY, CA--(Marketwired - Feb 6, 2017) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today the publication of a peer-reviewed substudy...
November 14, 2016 08:30 ET | Source: CardioDx

CardioDx Announces Final Endpoint Results from the PRESET Registry at the AHA Scientific Sessions 2016

REDWOOD CITY, CA--(Marketwired - Nov 14, 2016) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced results from the final endpoint analysis...
July 13, 2016 02:00 ET | Source: Motif Bio

Motif Bio Files Registration Statement for Proposed U.S. Public Offering of American Depositary Shares and Applies for NASDAQ Listing

LONDON, UNITED KINGDOM--(Marketwired - Jul 13, 2016) - Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it has...
June 01, 2016 08:30 ET | Source: CardioDx

Khush F. Mehta Joins CardioDx as Chief Executive Officer

REDWOOD CITY, CA--(Marketwired - Jun 1, 2016) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today the appointment of Khush Mehta as President,...
May 21, 2016 12:00 ET | Source: CDx Diagnostics

New Data Demonstrate That WATS3D Is 4X More Effective Than the Seattle Random Biopsy Protocol in the Detection of High-Grade Dysplasia and Esophageal Adenocarcinoma

SUFFERN, NY--(Marketwired - May 21, 2016) - CDx Diagnostics today announced final data from a multicenter, prospective, randomized, crossover study demonstrating a fourfold increase in the detection...

Next Page keyboard_arrow_right